MDVN). In that article, I said: "I do wonder, though, how JNJ will respond to increased competition and further threats of weakening margins. "Companies like Medivation -- which has a strong oral medication drug that rivals Zytiga -- should not be taken lightly. This is where JNJ's extraordinarily well-diversified business should offset potential near-term headwinds."
Given that Johnson & Johnson is willing to pay a king's ransom for ARN-509, it's highly doubtful the company intends to lose out in any court case, especially since Medivation would still need to prove that it is the right-holder of the drug. Follow @saintssense This article was written by an independent contributor, separate from TheStreet's regular news coverage.